Module 4: Case Studies for the Development of Specialty Biotherapeutics (Part 1 & 2)

Recorded On: 05/22/2023

image
image


Part 1: Case Studies for the Development of Specialty Biotherapeutics–Oncolytic Virus Practical Considerations for Nonclinical Development and Case Study

Oncolytic viruses represent an important emerging class of anticancer agents. Historically, viruses were used to treat cancer beginning over 100 years ago. The evolution of oncolytic viruses has advanced to genetically engineered viruses designed to have enhanced tumor selectivity and, more recently, to “armed” oncolytic viruses encoding transgenes intended to improve selectivity or immune stimulation. Significant advances include the milestone first approval of an oncolytic virus to treat cancer with the FDA approval of talimogene laherparepvec (T Vec), an engineered herpes simplex virus. Various oncolytic viruses from diverse viral families have advanced into clinical studies. The promise of OVs is that they offer direct tumor cell killing as well as immune stimulation, making them ideal combination partners for immuno-oncology agents such as checkpoint inhibitors. Newcastle disease virus (NDV) is a negative-strand RNA virus from the family paramyxoviridae that causes disease in avian species (the natural host). The anticancer potential of a mesogenic strain of NDV has been investigated in several clinical studies with mixed success. Since it was classified as a select agent because of its pathogenicity in chickens, the clinical development of NDV as an oncolytic agent has been challenging. MEDI5395 is a recombinant strain of NDV which has been engineered to express granulocyte/ macrophage colony-stimulating factor (GM-CSF). The nonclinical safety assessment strategy employed, including study design challenges, regulatory requirements, and critical study endpoints such as biodistribution, transgene expression, and shedding, will be described.

Part 2: Case Studies for the Development of Specialty Biotherapeutics

The aim of the presentation will be to present a number of case studies for different types of immuno-oncology drugs, including T cell engagers, immunostimulatory antibody-drug conjugates (ISACs), protein-based cancer vaccines and immunostimulatory adjuvants, and mRNA-based immunomodulators. These case studies will highlight some of the key challenges in the non-clinical safety assessment of these molecules and entry into the clinic. Topics covered will include candidate design and optimization to minimize adverse safety events/immunogenicity, in vitro safety studies with human cells, assessing potential for off-tumor/on-target and off-target binding, species selection and qualification for in vivo pharmacology and toxicology studies, design of Dose Range-Finding (DRF) and IND-enabling GLP toxicity studies and inclusion of PK, PD, and safety endpoints, immunogenicity assessment, and First-In-Human (FIH) dose selection (balancing the risk-benefit to cancer patients and so not starting too low). Regulatory expectations will also be highlighted.

Michelle Coulson, PhD, ERT

Michelle Coulson, PhD, ERT

Toxicology Project Leader

Novartis

Dr. Michelle Coulson earned her PhD in Molecular Toxicology from the University of Surrey, UK. She is currently a Toxicology Project Leader in the Department of Preclinical Safety at Novartis Institutes for Biomedical Research in Cambridge, Massachusetts. She has over 19 years of experience in preclinical safety assessment in the pharmaceutical industry supporting a diverse range of small molecules, monoclonal antibodies, bi-/tri-specific antibodies and antibody-drug conjugates. Dr. Coulson holds a board certification from the ERT.

Patricia Ryan, PhD

Patricia Ryan, PhD

Senior Director, Clinical Pharmacology and Safety Sciences

AstraZeneca

Dr. Patricia Ryan has over 30 years of experience in the biopharmaceutical industry with an emphasis on nonclinical safety testing of biologics and vaccines. Currently, she is the Strategic Toxicology Lead for Infectious Diseases at AstraZeneca and leads nonclinical safety strategy for this therapy area in Safety Sciences. Before that, she directed toxicology in Biologics Safety Assessment at MedImmune. 

Dr. Ryan is currently President of the American College of Toxicology. She has been an active member of ACT since 2004. She was elected to the Education Committee in 2008 and to Council in 2012. While on Council, she chaired the Education Committee. She served as ACT Secretary from 2021–2022. She has served on the Program Committee multiple times. She is also a member of the Society of Toxicology and represents AZ on the IQ Consortium DruSafe Leadership Group.

Dr. Ryan obtained her bachelor’s degree in chemistry from the University of Virginia and her PhD in chemistry from Johns Hopkins University. She trained as a postdoctoral scientist at SmithKline Beecham (now GlaxoSmithKline).

Key:

Complete
Failed
Available
Locked
Module 4: Case Studies for the Development of Specialty Biotherapeutics (Part 1 and 2)
Module 4: Case Studies for the Development of Specialty Biotherapeutics (Part 1: Patricia Ryan, PhD, and Part 2: Michelle Coulson, PhD, ERT)
Recorded 05/22/2023  |  90 minutes
Recorded 05/22/2023  |  90 minutes As part of your registration, you will have unlimited access to the module recording for 30 days. Your 30-day access period begins when you first access the recording. Once the access period begins, it cannot be reset or restarted. To receive a certificate of completion, you must watch the recording for the minimum required viewing time. Please keep the recording open while viewing, as the system tracks your viewing time during the active session. If you close your browser before meeting the minimum viewing requirement, your viewing progress may not be retained. Once you have met the viewing requirement, the module survey will become available. After completing the survey, you will be able to access and download your certificate of completion. If you have any questions, please contact ACT Headquarters at [email protected].
Survey
13 Questions
13 Questions ACT values your feedback. Please help us continue to provide high-quality educational offerings by completing this short survey. The survey will become available after you have met the minimum viewing requirement for the recording. Once you complete the survey, your certificate of completion will become available on your dashboard or for download.
Certificate
No credits available  |  Certificate available
No credits available  |  Certificate available Your certificate of completion will become available after you have met the minimum viewing requirement and completed the module survey.